

1 **The effect of intimate partner violence on women’s risk of HIV acquisition and**
2 **engagement in the HIV treatment and care cascade: an individual-participant data**
3 **meta-analysis of nationally representative surveys in sub-Saharan Africa**
4

5 Kuchukhidze S¹ MPH, Panagiotoglou D¹ PhD, Boily MC² PhD, Diabaté S^{3,4,5} MD, Eaton JW²
6 PhD, Mbofana F⁶ MD, Sardinha L⁷ PhD, Schrubbe L⁸ MSc, Stöckl H⁹ PhD, Wanyenze RK¹⁰
7 PhD, and Maheu-Giroux M¹ ScD *

8
9
10 **Affiliations**

11 1- Department of Epidemiology, Biostatistics and Occupational Health, McGill University,
12 Montréal, Canada

13 2- Medical Research Council (MRC) Centre for Global Infectious Disease Analysis, School of
14 Public Health, Imperial College London, London, United Kingdom

15 3- Département de médecine sociale et préventive, Université Laval, Québec, QC Canada

16 4- Centre de recherche du CHU de Québec, Université Laval, Québec, QC, Canada

17 5- Université Alassane Ouattara, Bouaké, Côte d’Ivoire

18 6- Conselho Nacional de Combate ao HIV/Sida, Maputo, Mozambique

19 7- School for Policy Studies, University of Bristol, Bristol, United Kingdom

20 8- Department of Population Health, Faculty of Epidemiology and Population Health, London
21 School of Hygiene & Tropical Medicine, London, UK

22 9- Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig
23 Maximilian University of Munich, Munich, Germany

24 10- Department of Disease Control and Environmental Health, School of Public Health, College
25 of Health Sciences, Makerere University, Kampala, Uganda

26
27
28
29 ***Corresponding author**

30 Mathieu Maheu-Giroux

31 2001 Avenue McGill College, Suite 1200

32 Montréal, Québec

33 H3A 1G1, CANADA

34 mathieu.maheu-giroux@mcgill.ca

35 **Abstract**

36

37 **Background:**

38 Achieving the 95-95-95 targets for HIV diagnosis, treatment, and viral load suppression (VLS)
39 to end the HIV/AIDS epidemic hinges on eliminating structural inequalities, including intimate
40 partner violence (IPV). Sub-Saharan Africa (SSA) has among the world's highest prevalence of
41 IPV and HIV. We aim to examine the impact of IPV on recent HIV infection and women's
42 engagement in the HIV care cascade.

43

44 **Methods:**

45 We pooled individual-level data from nationally representative surveys with information on
46 physical and/or sexual IPV and HIV in SSA (2000-2020). We used Poisson regressions with
47 robust standard errors to estimate adjusted prevalence ratios (aPR) of past year experience of IPV
48 on recent HIV infection (measured using recency assays), past-year HIV testing, antiretroviral
49 therapy (ART) uptake, and VLS among ever-partnered (currently/formerly married or
50 cohabitating) women. Models were adjusted for women's age, age at sexual debut, residence
51 type, marital status, education, and the survey's identifier (proxy of country and year).

52

53 **Findings:**

54 Fifty-seven surveys were available from thirty countries, encompassing 280,259 (N_i) individuals.
55 One-fifth of women reported physical and/or sexual IPV in the past year. Six surveys had
56 information on recent HIV infection and seven had data on ART uptake and VLS. Women
57 experiencing past year IPV were 3.22 times (95%CI: 1.51-6.85, $N_i=19,179$) more likely to have
58 a recent HIV infection, adjusting for potential confounders. Past year IPV was not associated
59 with HIV testing (aPR=0.99, 95%CI: 0.98-1.01, $N_i=274,506$) or ART uptake (aPR=0.96,
60 95%CI:0.90-1.03, $N_i=5,629$). Women living with HIV (WLHIV) experiencing IPV in the past
61 year were 9% less likely to achieve VLS (aPR=0.91, 95%CI: 0.85-0.98, $N_i=5,627$).

62

63 **Interpretation:**

64 Past year IPV was associated with recent HIV acquisition and lower VLS among WLHIV.
65 Preventing IPV is inherently imperative but eliminating IPV could also be crucial to ending
66 HIV/AIDS.

67

68 **Funding:**

69 Canadian Institutes of Health Research, Canada Research Chair, and Max E. Binz Fellowship

70

71

Research in Context

Evidence before this study

Our study builds on more than two decades of research devoted to IPV and HIV.¹⁻⁴ We summarized this scholarship by searching PubMed for empirical studies (April 8, 2022), without language restrictions using the terms: HIV AND women AND (violence OR intimate partner OR domestic violence OR GBV OR IPV) AND (Africa* OR sub-Sahara*).

Several systematic and scoping reviews have been conducted on the links between IPV and HIV with mixed results.⁵⁻⁷ Most studies used HIV seropositivity as the outcome. In sub-Saharan Africa, a multi-country study found no association between IPV and HIV; however it has been subsequently suggested that women experiencing IPV have an increased risk of HIV seropositivity depending on the chosen referent group.⁸ Longitudinal studies in Uganda and South Africa suggest that women experiencing IPV are more likely to acquire HIV compared to those who are not.^{9,10} However, two other cohort studies among youth¹¹ and serodiscordant couples¹² did not find significant associations.

Impacts of IPV on the HIV prevention and treatment cascade have also been studied. A 2015 meta-analysis of 13 cross-sectional studies, mostly from the United States, found that IPV is associated with lower ART use, adherence and VLS.¹³ For the first step in the cascade – HIV diagnosis – most included studies in a 2019 scoping review by Leddy¹⁴ did not find an association between IPV and HIV testing¹⁵⁻¹⁹; though two reported a reduction in testing associated with IPV among pregnant and postpartum women.^{20,21}

Evidence supports a negative relationship between IPV and ART adherence, though most studies focused on populations such as sex workers¹⁷, youth²², or pregnant/postpartum women.^{18,23-25} Quantitative evidence are sparse on ART *uptake*, but among five studies from high income settings, none showed an association between IPV and *current* ART use.¹³ Studies from Zambia and South Africa point to an association between IPV and unsuppressed viral loads among adolescents/youth²⁶ and postpartum women.²⁷

Overall, comparison of estimates and outcomes is difficult due to a lack of standardization in survey instruments, recall period for IPV, considered IPV types, outcome measurement, and populations considered (e.g., pregnant and/or young women, sex workers).

Added value of this study

Using microdata from population-based surveys in the region with the highest HIV burden, we conducted the largest and most comprehensive study to date on the impacts of IPV on HIV: from HIV acquisition to the three most important steps of the treatment and care cascade. Our results generally corroborate previous findings, but we considerably expanded the scope of previous studies using recent experiences of IPV, consideration of partner characteristics, and estimating their impact on biomarker-based measures of HIV acquisition, ART coverage, and VLS.

The implications of all the available evidence

The *2021 Political Declaration on AIDS* commits to eliminating sexual and gender-based violence, including IPV as key to combatting the AIDS epidemic. IPV is an urgent public health concern, and a barrier to the elimination of AIDS. Our results highlight the need for HIV programs to consider IPV along the full continuum of HIV prevention to treatment and care. Both IPV and HIV are preventable. Governments, societies, and communities need to explicitly recognize the IPV-HIV syndemic, and implement multisectoral response with social and economic components to eliminate gender-based violence and end AIDS.

73 Introduction

74 Despite significant progress to curb HIV epidemics worldwide, 1.5 million new HIV
75 infections occurred in 2020, over 60% of which were in sub-Saharan Africa.²⁸ This burden of
76 new infections disproportionately affects women: they account for 65% of new HIV infections in
77 sub-Saharan Africa.^{28,29} The global HIV agenda is guided by the “95-95-95” targets to end AIDS
78 by 2030 — an ambitious plan that calls for achieving 95% diagnosis coverage, 95%
79 antiretroviral therapy (ART) uptake among those diagnosed, and 95% of viral suppression
80 among those on treatment.³⁰ Reaching these targets partly hinges upon addressing structural
81 vulnerabilities such as inequitable gender and social norms, and violence against women and
82 girls. Worldwide, over one in four women has experienced physical and/or sexual intimate
83 partner violence (IPV) in their lifetime, with prevalence reaching highs of approximately 40% in
84 Central and Eastern sub-Saharan Africa.³¹ This violence often co-occurs with HIV and could
85 function as a syndemic, posing barriers to women’s ability to prevent HIV acquisition, to access
86 HIV care, and to remain in care if living with the virus. The *2021 United Nations General*
87 *Assembly* adopted the *Political Declaration on HIV and AIDS* with bold new global targets for
88 2025, which commit to elimination of all forms of sexual and gender-based violence, including
89 IPV as a key enabler of the HIV epidemic.³² Improving our understanding of the complex
90 relationships between IPV and HIV is essential to meet this commitment.

91 In sub-Saharan Africa, women being subjected to IPV could be at increased risk of HIV
92 acquisition.⁸⁻¹⁰ Beside this potential impact on HIV incidence, IPV could compromise access to
93 the HIV prevention and care cascade³³: from HIV testing, to ART uptake and retention^{14,17,22,34},
94 and ultimately, to viral load suppression (VLS).^{13,14,26} Overall, evidence suggesting that IPV and
95 HIV interact in a syndemic way could be strengthened. Previous studies either provided mixed
96 results, focused on a single country, and/or recruited specific populations such as pregnant
97 women,³⁴ youth²², female sex workers¹⁷, or women who use substances.³⁵ This makes
98 generalization of the study’s results challenging. Furthermore, the definitions of IPV (e.g.,
99 severity of acts, physical only, sexual only, or both), the period (e.g., lifetime or past year), and
100 sampling strategies (e.g., currently partnered or ever-partnered) have varied, making it difficult
101 to systematically compare effect size estimates, and generate robust evidence on population-level
102 effects of IPV.¹⁴ Over the last decade, several large, nationally-representative, population-based
103 surveys have collected information on IPV and HIV, including recency assays, ART biomarkers,
104 and VLS. These surveys use standardized and robust methodology, providing researchers
105 opportunities to overcome the limitations of previous studies.

106 Our overarching aim was to improve understanding of the complex relationships between
107 women’s experience of IPV and HIV acquisition, and engagement with the HIV prevention and
108 treatment cascade.^{2,3,33} To achieve this, we estimated the impact of recent (past 12 months)
109 physical and/or sexual IPV on the following four outcomes: recent HIV infection, self-reported
110 HIV testing in the past year, ART uptake, and VLS.

111

112 **Methods**

113 *Data sources and study population*

114 We reviewed all available nationally-representative, cross-sectional, population-based
115 surveys from sub-Saharan Africa over 2000-2020 with individual participant data on both IPV
116 and HIV. We searched data catalogs (i.e., the *Global Health Data Exchange*, the *International*
117 *Household Survey Network*), examined surveys included in the Global Estimates for Violence
118 Against Women Statistics systematic review³⁶, a previous review of surveys with information on
119 HIV testing³⁷, and complemented these with expert knowledge.

120 The types of surveys considered included *Demographic and Health Surveys* (DHS), *AIDS*
121 *Indicator Surveys* (AIS) (<https://dhsprogram.com/Data/>), *Population-based HIV Impact*
122 *Assessment* (PHIA) (<https://phia-data.icap.columbia.edu/datasets>) and *South Africa National HIV*
123 *Prevalence, Incidence, Behavior and Communication Survey* (SABSSM)
124 (<http://datacuration.hsrc.ac.za/search/browse/alpha/S>), as well as country-specific surveys (e.g.,
125 *Botswana AIDS Impact Survey*, *Kenya AIDS Indicator Surveys*, and *Nigeria HIV/AIDS Indicator*
126 *and Impact Survey*). Study population included all ever-partnered (currently or formerly married
127 or cohabitating) women and girls aged ≥ 15 years (Figure 1).

128 *Measurement of experience of IPV*

129 In all surveys, data on IPV was collected from one randomly selected woman in each
130 household for PHIA and SABSSM, and from a fraction of households in DHS/AIS (usually one
131 third). The primary exposure of interest was experience of physical and/or sexual IPV in the past
132 year (Supplement 1; Table S1). All surveys used acts-specific, gold-standard instruments based
133 on the modified *Conflict Tactics Scale* to collect information on IPV.^{38,39}

134 The secondary exposures of interest were a) lifetime experience of physical IPV only, b)
135 lifetime experience of sexual IPV only, c) lifetime experience of physical and/or sexual IPV, d)
136 lifetime experience of severe physical and/or sexual IPV, and d) frequent past year experience of
137 physical and/or sexual IPV. Measurements are generally consistent across surveys, although
138 PHIA collected information on past year IPV only (no lifetime measure) (Supplement 1; Table
139 S1) and in SABSSM, past year IPV pertains to physical violence only (i.e., no information on
140 sexual violence).

141 Severity of lifetime IPV was collected only in the DHS and SABSSM (number of
142 surveys, $N_{\text{surv}}=52$). Severe IPV was defined as lifetime experience of severe physical and/or
143 sexual IPV, which includes punching, kicking/dragging, trying to strangle/burn, threatening with
144 a weapon, attacking with a weapon, and any type of sexual IPV.⁴⁰ (Supplement 1; Table S1)

145 Frequency of past year physical and/or sexual IPV was categorized as “often”,
146 “sometimes”, or “never”. In PHIA, the frequency question pertains to the experience of physical
147 violence by any perpetrator in the past year, and we assumed this to be an intimate partner only if
148 the participant reported IPV as well (Supplement 1; Table S1). Further, in the SABSSM and
149 PHIA surveys, the frequency of past year IPV pertains to only physical IPV while in other
150 surveys the indicator refers to frequency of physical and/or sexual IPV. Whenever the survey did
151 not collect the information, we extrapolated the frequency of physical IPV to that of physical

152 and/or sexual IPV based on the strong relationship between both measures (X-squared = 43,780,
153 $p < 0.05$).

154 *Outcome measurements*

155 Our primary outcome is recent HIV infection (as a proxy for HIV incidence) among
156 women at risk of HIV acquisition (i.e., excluding those living with non-recent HIV). Recency
157 was measured via LAg assay performed on all participants found to be seropositive for HIV. The
158 algorithm to identify recent infections –those that were acquired less than four to seven months
159 before sample collection^{41,42}– accounted for ART biomarkers and VLS to minimize false
160 positives.⁴³

161 Other outcomes concern the HIV prevention and treatment cascade. (Supplement 1;
162 Table S2) First, we considered self-reported HIV testing histories (lifetime and past year testing
163 and receipt of result). Second, ART uptake was measured among ever-partnered women living
164 with HIV (WLHIV) based on either ART biomarkers or self-reports of currently taking ART.
165 Finally, WLHIV were considered virally suppressed if their HIV RNA viral load was < 1000
166 copies/mL. Women with a recent HIV infection were excluded from the ART uptake and viral
167 suppression analyses (Supplement 1; Table S2).

168 *Statistical analyses*

169 Individual-level data from each survey were pooled to calculate crude and adjusted
170 prevalence ratios (PR) for the association between IPV and recent HIV infection, HIV testing,
171 ART uptake and VLS. Adjusted prevalence ratios (aPR) were estimated accounting for potential
172 confounders such as: women's age, residence type (rural/urban), women's marital status,
173 women's education, and survey-level fixed effects (survey country and year). An additional
174 adjustment variable for the HIV recency analysis was age at sexual debut. These confounders
175 were available from all surveys and had been previously identified as being potentially linked to
176 both IPV and the outcomes.⁴⁴⁻⁴⁸ The survey-level fixed effects allowed us to control for any
177 measured/unmeasured survey-level confounders.

178 Modified Poisson regression models were used to obtain the crude and adjusted PR based
179 on Generalized Estimating Equations (GEE) with robust standard errors that accounted for the
180 sampling design (i.e., exchangeable correlation structure with the primary sampling units as the
181 clustering variable). Survey weights were not included in the regression^{8,49} as they are often
182 unwarranted to obtain unbiased estimates.⁵⁰ We used a complete case analysis since the
183 proportion of missing observations was small for all outcomes ($\leq 4\%$). Supplemental materials
184 include information on the missing observations and the analyses of potential biases (Supplement
185 2). The R software (4.0.0) and the 'geepack' package were used for all analyses.⁵¹

186 *Sensitivity analyses*

187 In sensitivity analyses we examined the robustness of our results by only including
188 women testing outside of the antenatal care (ANC) in the analyses of HIV testing to examine if
189 IPV has a differential impact by testing modality. We restricted the analysis of VLS to women
190 on ART (i.e., conditioning on achieving this step in the cascade). To investigate if partner or

191 couple's characteristics confound the relationship between IPV and HIV acquisition we linked
192 data for married or cohabiting men and women who both declared to be co-habiting. We then
193 calculated proportions of male partners living with HIV, male partner age, partner education,
194 partner alcohol consumption, mean partner age discrepancy and condom use at women's most
195 recent sex, stratified by experience of past year IPV.

196 All analyses were performed using secondary, de-identified data. DHS/AIS survey
197 protocols are approved by the Internal Review Board of ICF International in Calverton (USA)
198 and by the relevant country authorities for other surveys. Approval for data analyses was
199 obtained from *McGill University's Faculty of Medicine and Health Sciences Institutional Review*
200 *Board (A12-B95-21B)*.


201 *Role of the funding source*

202 The funders had no role in the study's design, data analysis, interpretation, manuscript
203 writing, and decision to publish.

204 **Results**

205 *Description of included surveys*


206 We identified 100 nationally representative surveys that included information on HIV
207 testing (the most reported outcome), of which 64 were included in the HIV testing analysis and
208 had data on IPV (51 DHS/AIS, 5 PHIA, 1 SABSSM) (Figure 1). After excluding 7 surveys, the
209 resulting 57 surveys were conducted in 30 countries and included 280,259 unique female
210 respondents aged 15-64 years (Supplement 3; Table S6). Women with missing data for all
211 exposures of interest were excluded. Fifteen countries had more than one included survey and
212 the median year of data collection was 2013. Most surveys were from Eastern Africa (51%).
213 Only 10% of surveys had information on recent HIV infection ($N_{\text{surv}}=6$) and 12% had data on
214 ART uptake and VLS ($N_{\text{surv}}=7$) (Figure 2).



215

216 **Figure 1. Flowchart for survey inclusion/exclusion for each type of analysis: recent HIV infection, HIV testing,**
 217 **antiretroviral (ART) uptake and viral load suppression (VLS).** We did not use 7 surveys with data on intimate
 218 partner violence (IPV) since information on past year physical IPV were not collected ($N_{surv}=3$) or information about
 219 HIV and intimate partner violence was gathered from different subgroups of women ($N_{surv}=2$) (i.e., HIV questions in
 220 the DHS were asked to women in households which were selected for the men's survey). We removed two surveys
 221 (Côte d'Ivoire PHIA 2017 and Cameroon PHIA 2017) where over 95% of past year IPV data were missing.
 222 (AIS=AIDS Indicator Survey; DHS=Demographic and Health Survey; Excl.=excluded; IPV=intimate partner
 223 violence; PHIA=Population-based HIV Impact Assessment Survey; SABSSM=South African National HIV
 224 Prevalence, Incidence, Behaviour and Communication Survey.)

225



226

227 **Figure 2. Surveys with questions on HIV and intimate partner violence (IPV), by country and year, 2000-2020.**

228 *Points represent population-based surveys conducted in sub-Saharan Africa from 2000-2020 and asking about HIV*
 229 *testing and intimate partner violence (IPV). Circles represent survey types. Different shapes indicate the type of*
 230 *analyses the surveys were included in a) only HIV testing b) HIV testing, antiretroviral (ART) uptake and viral load*
 231 *suppression (VLS), c) testing, ART uptake and VLS, and recent HIV infection. (AIS=AIDS Indicator Survey;*
 232 *ART=antiretroviral treatment; DHS=Demographic and Health Survey; Inc=HIV incidence (recent HIV infection);*
 233 *PHIA=Population-based HIV Impact Assessment Survey; SABSSM=South African National HIV Prevalence,*
 234 *Incidence, Behaviour and Communication Survey; VLS=viral load suppression.)*

235 *Study population*

236 Overall, over one fifth (21%) of all ever-partnered women had experienced physical
 237 and/or sexual IPV in the past year and 29% in their lifetime. Central Africa had the highest
 238 prevalence of past year physical and/or sexual (29%) IPV, followed by Eastern Africa (23%)
 239 (Supplement 3; Table S6). Women who had experienced past year physical and/or sexual IPV
 240 were younger than those who had not, across the pooled surveys included in all the analyses
 241 (Supplement 4; Table S7-S10). Among women not living with HIV, close to half of those
 242 reporting IPV in the past year had only primary education, compared to 36% of those who did
 243 not report IPV (Supplement 4; Table S7). Most women living with HIV, irrespective of reporting
 244 IPV, had secondary education (Supplement 4; Table S8-S10).

245 *Recent HIV infection*

246 Among the six surveys with information on recent infections, a total of 45 women had
247 recently acquired HIV (Table 1). Women not living with HIV who had not experienced past year
248 physical and/or sexual IPV had 0.5%-point higher proportion of recent HIV infections compared
249 to those who had. The crude PR for recent HIV infections is 3.50 (95%CI: 1.63-7.51, $N_{\text{surv}}=6$;
250 Table 2). Adjusting for potential confounders, women who had experienced past year IPV were
251 3.22 times more likely (95%CI: 1.51-6.85, $N_{\text{surv}}=6$) to have a recent HIV infection than those
252 who had not experienced IPV. (Table 2)

253 As a robustness check, we examined the HIV status of the cohabiting partners, partners'
254 age discrepancy, partner education, partner alcohol consumption, and condom use at women's
255 last sex as potential confounders in the six surveys included in the recent HIV infection analysis
256 (Supplement 5; Table S11-S14). Partner age discrepancy and partner alcohol consumption varied
257 between women having experienced past year IPV and those who had not; however the effect
258 estimates are robust to confounding by these variables.

259

260 **Table 1.** Unweighted proportion of women and the number of analyzed surveys with each outcome of interest: recent HIV infection, lifetime HIV testing, past
 261 year HIV testing, antiretroviral therapy (ART) uptake and viral load suppression (VLS).

| Outcome [‡] | Past year physical and/or sexual IPV | | | Lifetime physical IPV | | | Lifetime sexual IPV | | | Lifetime physical and/or sexual IPV | | |
|------------------------------|--------------------------------------|-------------------|--------------------|-----------------------|-------------------|--------------------|---------------------|-------------------|--------------------|-------------------------------------|-------------------|--------------------|
| | Surveys (N) | Yes | No | Surveys (N) | Yes | No | Surveys (N) | Yes | No | Surveys (N) | Yes | No |
| Recent HIV infection, n (%) | | | | | | | | | | | | |
| Yes | 6 | 8 (0.7%) | 37 (0.2%) | 1 | 2 (0.5%) | 2 (0.1%) | 1 | 0 (0%) | 4 (0.2%) | 1 | 2 (0.5%) | 2 (0.1%) |
| No | | 1,150 (99.3%) | 18,740 (99.8%) | | 425 (99.5%) | 2,044 (99.9%) | | 85 (100%) | 2,384 (99.8%) | | 438 (99.5%) | 2,031 (99.9%) |
| Lifetime HIV testing, n (%) | | | | | | | | | | | | |
| Yes | 57 | 31,023 (52.5%) | 113,384 (52.4%) | 52 | 39,531 (53.8%) | 83,757 (46.2%) | 52 | 15,663 (55.2%) | 107,624 (47.6%) | 52 | 43,802 (54.0%) | 79,483 (45.8%) |
| No | | 28,101 (47.5%) | 102,976 (47.6%) | | 33,908 (46.2%) | 97,446 (53.8%) | | 12,704 (44.8%) | 118,614 (52.4%) | | 37,347 (46.0%) | 93,986 (54.2%) |
| Past year HIV testing, n (%) | | | | | | | | | | | | |
| Yes | 57 | 16,392 (27.8%) | 57,996 (26.9%) | 52 | 20,292 (27.7%) | 43,451 (24.0%) | 52 | 8,240 (29.1) | 55,506 (24.6) | 52 | 22,555 (27.9%) | 41,189 (23.8%) |
| No | | 42,601 (72.2%) | 157,969 (73.1%) | | 52,993 (72.3%) | 137,456 (76.0%) | | 20,080 (70.9%) | 170,329 (75.4%) | | 58,429 (72.1%) | 131,995 (76.2%) |
| ART uptake, n (%) | | | | | | | | | | | | |
| Yes | 7 | 416 (64.2%) | 3,717 (71.3%) | 2 | 388 (64.8%) | 675 (60.5%) | 2 | 68 (66.7%) | 996 (61.7%) | 2 | 402 (64.9%) | 661 (60.3%) |
| No | | 232 (35.8%) | 1,498 (28.7%) | | 211 (35.2%) | 441 (39.5%) | | 34 (33.3%) | 618 (38.3%) | | 217 (35.1%) | 435 (39.7%) |
| VLS, n (%) | | | | | | | | | | | | |
| Yes | 7 | 375 (56.7%) | 3,506 (67.3%) | 2 | 348 (57.0%) | 645 (57.3%) | 2 | 60 (60.6%) | 934 (57.0%) | 2 | 362 (57.4%) | 631 (57.1%) |
| No | | 286 (43.3%) | 1,700 (32.7%) | | 262 (43.0%) | 481 (42.7%) | | 39 (39.4%) | 704 (43.0%) | | 269 (42.6%) | 474 (42.9%) |

262 ART=antiretroviral therapy; IPV=intimate partner violence; Surv.=survey; VLS=viral load suppression.

263 [‡]Denominators for these proportions are the total number of women with or without each of the exposures of interest: past year physical and/or sexual IPV, lifetime physical IPV,
 264 lifetime sexual IPV, lifetime physical and/or sexual IPV.

265
266
267
268

Table 2. Crude and adjusted prevalence ratios of HIV recent infection among women experiencing past-year physical and/or sexual intimate partner violence (IPV) compared to women not experiencing this type of IPV.

| Exposures | N _{surv} | N _i | Crude PR (95% CI) | Adjusted PR [‡] (95% CI) |
|--|-------------------|----------------|----------------------|--------------------------------------|
| Primary exposure of interest[§] | | | | |
| Past year physical and/or sexual IPV | 6 | 19,179 | 3.50 (1.63, 7.51) | 3.22 (1.51, 6.85) |
| Secondary exposure of interest | | | | |
| Frequency of past year physical and/or sexual IPV [¥] | | | | |
| Never | 6 | 19,178 | Referent | Referent |
| Sometimes | | | 3.23 (1.36, 7.62) | 2.96 (1.27, 6.89) |
| Often | | | 4.75 (1.15, 19.7) | 4.50 (0.97, 20.85) |

269 95%CI=95% confidence intervals; IPV=intimate partner violence; N_{surv}=number of surveys; N_i=number of individual
270 observations without any missing data for intimate partner violence (IPV), the outcome and the covariates included in the model;
271 PR=prevalence ratio.

272 ‡ Adjusted for: age (continuous), age at sexual debut (continuous), residence type (rural/urban), women’s current marital status
273 (married/unmarried), women’s education (none, primary, secondary, higher), and survey identifier.

274 § 5/6 surveys included in the HIV acquisition analysis were PHIA (Population-based HIV Impact Assessment Survey), which
275 does not collect data on our secondary exposures of interest: lifetime physical IPV, lifetime sexual IPV, lifetime physical and/or
276 sexual IPV.

277 ¥ In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual
278 IPV. Furthermore, this question asks about perpetration of violence by “someone” which we assume to be an intimate partner
279 only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or
280 sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).

281 *HIV testing*

282 Self-reports of HIV testing in the past year were similar between women who had
283 experienced IPV and those who had not. About a quarter of women in both groups had been
284 tested in the past year (28% and 27% among those who experienced IPV and those who had not,
285 respectively) and nearly half of all women (regardless of experience of IPV in the past year) ever
286 tested for HIV (Table 1).

287 The crude PR of past year physical and/or sexual IPV on recent HIV testing was 0.98
288 (95%CI: 0.97-0.99). Adjusting for potential confounders, experience of past year IPV had no
289 effect on recent HIV testing (aPR=0.99, 95%CI: 0.98-1.01, N_{surv}=57). Women experiencing
290 lifetime physical and/or sexual IPV were 2% more likely to report lifetime testing (aPR= 1.02,
291 95%CI: 1.02-1.03, N_{surv}=52) (Table 3).

292 Similar results were obtained in sensitivity analyses where we excluded women who
293 reported testing at ANC. Experience of lifetime physical and/or sexual IPV was associated with a
294 small increase in lifetime HIV testing among women who tested outside of the ANC (aPR=1.04,
295 95%CI: 1.03-1.05, N_{surv}=52; Supplement 6; Table S15).

296
297

298 **Table 3.** Crude and adjusted prevalence ratios of lifetime and past year HIV testing among women experiencing
 299 different intimate partner violence (IPV) categories compared to women not experiencing a specific type of IPV.

| Outcomes | Exposures | N _{surv} | N _i | Crude PR (95% CI) | Adjusted PR‡ (95% CI) |
|--|--|-------------------|----------------|----------------------|--------------------------|
| Past year HIV testing | | | | | |
| Primary exposure of interest | | | | | |
| | Past year physical and/or sexual IPV | 57 | 274,506 | 0.98 (0.97, 0.99) | 0.99 (0.98, 1.01) |
| Secondary exposures of interest | | | | | |
| | Lifetime physical IPV | 52 | 254,041 | 0.99 (0.97, 1.00) | 1.00 (0.99, 1.01) |
| | Lifetime sexual IPV | 52 | 254,005 | 0.99 (0.98, 1.01) | 0.99 (0.97, 1.00) |
| | Lifetime physical and/or sexual IPV | 52 | 254,017 | 0.99 (0.98, 1.00) | 0.99 (0.98, 1.01) |
| | Severe lifetime physical and/or sexual IPV† | 52 | 253,977 | 0.97 (0.96, 0.99) | 0.98 (0.97, 0.99) |
| | Frequency of past-year physical and/or sexual IPV‡ | | | | |
| | Never | 57 | 274,505 | Referent | Referent |
| | Sometimes | | | 0.99 (0.98, 1.00) | 0.99 (0.98, 1.01) |
| | Often | | | 0.95 (0.92, 0.97) | 0.99 (0.96, 1.01) |
| Lifetime HIV testing | | | | | |
| Secondary exposures of interest | | | | | |
| | Lifetime physical IPV | 52 | 254,464 | 1.01 (1.00, 1.02) | 1.02 (1.02, 1.03) |
| | Lifetime sexual IPV | 52 | 254,428 | 1.00 (0.99, 1.01) | 1.01 (1.00, 1.01) |
| | Lifetime physical and/or sexual IPV | 52 | 254,440 | 1.01 (1.01, 1.02) | 1.02 (1.02, 1.03) |
| | Severe lifetime physical and/or sexual IPV§ | 52 | 254,399 | 1.00 (0.99, 1.01) | 1.01 (1.00, 1.02) |

300 95%CI=95% confidence intervals; IPV=intimate partner violence; N_{surv}=number of surveys; N_i=number of individual
 301 observations without any missing data for intimate partner violence (IPV), the outcome and the covariates included in the model;
 302 PR=prevalence ratio.

303 ‡ Adjusted for: age (continuous), residence type (rural/urban), women's current marital status (married/unmarried), women's
 304 education (none, primary, secondary, higher), and survey identifier.

305 † In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual
 306 IPV. Furthermore, this question asks about perpetration of violence by "someone" which we assume to be an intimate partner
 307 only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or
 308 sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).

309 ‡ Referent category includes women experiencing non-severe lifetime IPV and no lifetime IPV.

310 *Antiretroviral therapy uptake*

311 WLHIV who had reported past year physical and/or sexual IPV compared to those who
 312 had not had 7.1%-point lower ART uptake (Table 1). The crude PR for ART uptake was 0.90
 313 (95%CI: 0.85-0.96, N_{surv}=7). After adjustments, women who had reported past year IPV were
 314 4% less likely to be on ART, compared to those who had not (aPR=0.96, 95%CI: 0.90-1.03,
 315 N_{surv}=7), but we cannot rule out the absence of an effect. Severe lifetime IPV slightly increased
 316 the strength of the association with poor ART uptake (aPR=0.94, 95%CI: 0.84-1.05, N_{surv}=2),
 317 though this analysis was restricted to two surveys with information which decreased the
 318 precision of the estimate (Table 4).

319
 320
 321

322 **Table 4.** Crude and adjusted prevalence ratios of antiretroviral (ART) uptake among women living with HIV
 323 (WLHIV) experiencing different intimate partner violence (IPV) categories compared to WLHIV not experiencing a
 324 specific type of IPV

| Exposures | N _{surv} | N _i [§] | Crude PR (95% CI) | Adjusted PR [‡] (95% CI) |
|--|-------------------|-----------------------------|----------------------|--------------------------------------|
| Primary exposure of interest | | | | |
| Past year physical and/or sexual IPV | 7 | 5,629 | 0.90 (0.85, 0.96) | 0.96 (0.9, 1.03) |
| Secondary exposures of interest | | | | |
| Lifetime physical IPV | 2 | 1,569 | 1.06 (0.98, 1.14) | 1.00 (0.93, 1.08) |
| Lifetime sexual IPV | 2 | 1,570 | 1.08 (0.94, 1.24) | 1.05 (0.91, 1.21) |
| Lifetime physical and/or sexual IPV | 2 | 1,569 | 1.06 (0.98, 1.14) | 1.01 (0.94, 1.09) |
| Severe lifetime physical and/or sexual IPV [†] | 2 | 1,568 | 0.93 (0.83, 1.04) | 0.94 (0.84, 1.05) |
| Frequency of past-year physical and/or sexual IPV [¥] | | | | |
| Never | 7 | 5,629 | Referent | Referent |
| Sometimes | | | 0.91 (0.86, 0.97) | 0.96 (0.90, 1.03) |
| Often | | | 0.84 (0.71, 0.99) | 0.97 (0.82, 1.16) |

325 95%CI=95% confidence intervals; ART=antiretroviral treatment; IPV=intimate partner violence; N_{surv}=number of surveys;
 326 N_i=number of individual observations without any missing data for intimate partner violence (IPV), the outcome and the
 327 covariates included in the model; PR=prevalence ratio; WLHIV=women living with HIV.

328 [‡] Adjusted for: age (continuous), residence type (rural/urban), women's current marital status (married/unmarried), women's
 329 education (none, primary, secondary, higher), and survey identifier.

330 [¥] In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual
 331 IPV. Furthermore, this question asks about perpetration of violence by "someone" which we assume to be an intimate partner
 332 only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or
 333 sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).

334 [§] 0.7% of women were removed because they had a recent HIV infection and did not have time to be diagnosed and linked to
 335 treatment.

336 [†] Referent category includes women experiencing non-severe lifetime IPV and no lifetime IPV.

337 *Viral load suppression*

339 WLHIV who had experienced past year physical and/or sexual IPV compared to those
 340 who had not had 10.6%-point lower VLS (Table 1). The crude PR for VLS was 0.85
 341 (95%CI:0.79-0.91, N_{surv}=7). After adjusting for confounders, women who had experienced past
 342 year IPV were 9% less likely to be virally suppressed, compared to those who had not
 343 (aPR=0.91, 95%CI: 0.85-0.98, N_{surv}=7; Table 5). Lifetime physical and/or sexual IPV had an
 344 adverse effect on VLS as well, though the confidence interval includes the null (aPR=0.94,
 345 95%CI:0.86-1.02, N_{surv}=2).

346 We further looked at the effect of IPV on VLS, restricting to women on ART. The effect
 347 size estimate between past year IPV and VLS among WLHIV on ART was smaller. WLHIV on
 348 ART who had experienced past year IPV were 6% less likely to have VLS compared to women
 349 who had not (aPR=0.94, 95%CI: 0.90-0.99, N_{surv}=7; Supplement 6; Table S16). Higher
 350 frequency of IPV in the past year was associated with a 14% reduction in the likelihood of VLS
 351 although the estimates were imprecise (aPR=0.86, 95%CI: 0.72-1.02, N_{surv}=7).

352

353 **Table 5.** Crude and adjusted prevalence ratios of viral load suppression (VLS) among women living with HIV
 354 (WLHIV) experiencing different intimate partner violence (IPV) categories compared to WLHIV not experiencing a
 355 specific type of IPV.

| Exposures | N _{surv} | N _i [§] | Crude PR (95% CI) | Adjusted PR [‡] (95% CI) |
|--|-------------------|-----------------------------|----------------------|--------------------------------------|
| Primary exposure of interest | | | | |
| Past year physical and/or sexual IPV | 7 | 5,627 | 0.85 (0.79, 0.91) | 0.91 (0.85, 0.98) |
| Secondary exposures of interest | | | | |
| Lifetime physical IPV | 2 | 1,583 | 0.99 (0.91, 1.07) | 0.93 (0.85, 1.01) |
| Lifetime sexual IPV | 2 | 1,584 | 1.08 (0.91, 1.27) | 1.04 (0.88, 1.23) |
| Lifetime physical and/or sexual IPV | 2 | 1,583 | 1.00 (0.92, 1.08) | 0.94 (0.86, 1.02) |
| Severe lifetime physical and/or sexual IPV [†] | 2 | 1,582 | 0.99 (0.88, 1.12) | 1.01 (0.90, 1.14) |
| Frequency of past-year physical and/or sexual IPV [¥] | | | | |
| Never | 7 | 5,627 | Referent | Referent |
| Sometimes | | | 0.86 (0.8, 0.93) | 0.91 (0.84, 0.98) |
| Often | | | 0.74 (0.61, 0.91) | 0.89 (0.73, 1.09) |

356 95%CI=95% confidence intervals; IPV=intimate partner violence; PR=prevalence ratio; N_{surv}=number of surveys; N_i=number of
 357 individual observations without any missing data for intimate partner violence (IPV), the outcome and the covariates included in
 358 the model; VLS=viral load suppression; WLHIV=women living with HIV.

359 [‡] Adjusted for: age (continuous), residence type (rural/urban), women's current marital status (married/unmarried), women's
 360 education (none, primary, secondary, higher), and survey identifier.

361 [¥] In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual
 362 IPV. Furthermore, this question asks about perpetration of violence by "someone" which we assume to be an intimate partner
 363 only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or
 364 sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).

365 [§] 0.7% of women were removed because they had a recent HIV infection and did not have time to be diagnosed and linked to
 366 treatment.

367 [†] Referent category includes women experiencing non-severe lifetime IPV and no lifetime IPV.
 368
 369

370

371

372 Discussion

373 IPV is a human right violation, a global health concern, and our study shows that it could
374 contribute to HIV epidemics. In our pooled analysis of population-based surveys, women who
375 had experienced physical and/or sexual IPV over the past year were over 3 times more likely to
376 have acquired a recent HIV infection compared to those who had not. Although we did not find
377 evidence of the impact of past year IPV on HIV testing, WLHIV who experienced physical
378 and/or sexual IPV in the past year were 9% less likely to be virally suppressed. In line with the
379 *United Nations 2021 Political Declaration* to end gender inequalities perpetuating the
380 HIV/AIDS epidemic, the available evidence^{9,10} suggest that elimination of IPV could be partly
381 responsible for reductions in new HIV infections and improvements viral load suppression.⁵²

382 In sub-Saharan Africa, the links between IPV and HIV have previously been studied
383 using HIV prevalence as the outcome.^{5-8,49} Such study designs make it difficult to disentangle
384 temporality between experience of IPV and HIV acquisition. We leveraged recent infection
385 assays that were recently deployed in large population-based surveys such as PHIA, as a proxy
386 for HIV incidence. Our results align with previous cohort studies, but our effect size estimates
387 are larger.^{6,9,10} Longitudinal studies in South Africa and Uganda show that women who had been
388 subjected to physical or sexual IPV had 1.5 times the HIV incidence compared to those who had
389 not.^{9,10} Larger effect size in our study may be attributable to the exposure-driven selection bias in
390 cohort studies and/or generalizability of effect size estimates from randomized controlled trials
391 and cohort studies.^{9,10}

392 Pathways through which IPV can affect HIV acquisition are complex and multifaceted.
393 While the most direct path is through sexual assault, a growing body of evidence suggests that at
394 the population level, structural factors surrounding IPV play a larger role.^{53,54} Men who
395 perpetrate IPV may be more likely to have a high number of concurrent sexual partners, use
396 condoms inconsistently, and use substances, and thus are more likely to be living with HIV
397 which in turn could lead to HIV transmission to their partners.⁵⁴⁻⁵⁸ Crude, descriptive evidence
398 from our study suggests that the proportion of partners who are living with HIV and condom use
399 at last sex are comparable between women experiencing and not experiencing IPV in the past
400 year. Partner age discrepancy and partner alcohol consumption varied between women who had
401 experienced IPV and those who had not, but the effect estimates remained robust to confounding
402 by these covariates.

403 Knowledge of HIV status among WLHIV –the first step in the cascade– can be a key
404 bottleneck in the HIV care cascade. In our study, IPV did not impact HIV testing, even after
405 excluding women who had tested at ANC (as HIV testing at ANC achieved high coverage).
406 Overall, evidence regarding the effect of IPV on HIV testing is mixed. Some studies suggested
407 lower rates of HIV testing due to a fear of violent reaction from one’s partner if the HIV test
408 comes back positive.^{20,25,59-61} Most studies from low-and middle-income countries found no
409 relationship, or even a positive relationship between IPV and HIV testing, which might be due to
410 a higher self-perceived risk among the IPV survivor.^{15,16,18,62,63} This is corroborated in our study,
411 where lifetime experience of physical and/or sexual IPV is associated with a small increase in
412 lifetime HIV testing, which might speak to the cumulative nature of lifetime experience of IPV
413 and associated high self-perceived risk. Null results could also be reflective of the unprecedented
414 scale-up of HIV-testing in sub-Saharan Africa in the past decade.³⁷

415 Our results suggest that women who had experienced past year IPV were less likely to be
416 on ART, compared to those who had not, though our results were not conclusive. Most existing
417 studies conducted in low- and middle-income countries look at the effects of IPV on ART
418 adherence. Those that assessed current ART use did not uncover relationships between the two,
419 which aligns with our results.¹³ However, we found that IPV was adversely associated with VLS,
420 even among women who are on ART, which implies that ART adherence could be the bottleneck
421 in WLHIV's success in the HIV care cascade. Pathways through which IPV affects ART uptake
422 and adherence are complex. Some women might hide their HIV status due to fear of their
423 partner's reaction, making it difficult to enroll in HIV care and adhere to treatment.^{14,64-66} IPV
424 could restrict women's access to healthcare through male control of resources, and freedoms of
425 mobility and decision-making.⁶⁷⁻⁶⁹

426 Our results should be interpreted considering the study's limitations. First, all surveys
427 depend on self-reports of IPV and might be subject to under-reporting due to their sensitive
428 nature.⁷⁰ However, the surveys used appropriate measures to ensure confidentiality. HIV testing
429 was also self-reported, though evidence shows that self-reported HIV-testing histories are
430 generally robust.⁷¹ Second, some of the included surveys slightly differed in terms of their
431 question wordings on IPV (e.g., frequency of past-year violence was a continuous variable and
432 had to be categorized). Nevertheless, questions were all acts-based and modified from the
433 *Conflict Tactics Scales*.³⁸ Third, we did not include emotional violence in the definition of
434 intimate partner violence, due to a lack of consensus on how to define, conceptualize, and
435 measure this construct cross-culturally.⁷² Fourth, few surveys had information on recent HIV
436 infection, ART uptake and VLS as compared to HIV testing histories. However, pooling all data
437 sources allowed us to improve the precision of our estimates. Fifth, we used cross-sectional
438 survey data and reverse causality remains a possibility. This limitation was alleviated, however,
439 by restricting our main exposure to recent IPV, examining recent HIV infection, and ART uptake
440 and VLS at the time of the interview. Sixth, non-response could threaten the validity of our
441 results, leading to selection bias and potential underestimation of the effect size measure
442 (Supplement 2). Finally, our descriptive analyses of male partner characteristics were based on a
443 small sample, and we cannot rule out residual confounding.

444 Strengths of our study include a comprehensive analysis of available population-based
445 surveys with information on IPV and HIV. Second, our large sample size allowed us to estimate
446 the adjusted prevalence ratios for the relationships between IPV, recent HIV infection and each
447 stage of the HIV treatment and care cascade. Finally, we conducted several sensitivity analyses
448 to assess the robustness of our findings.

449 Our results have important policy implications for HIV prevention and care delivery in
450 high HIV burden settings. At a service delivery-level, healthcare provider training should include
451 IPV-sensitive topics such as probing women in a nonjudgmental way to safely disclose their
452 experience of IPV. This could identify women at higher risk of disengagement from care who
453 can subsequently be linked to women-centric HIV services. Emergence of novel, patient-focused
454 HIV service delivery platforms, also known as "*differentiated service delivery*" models could
455 incorporate women-only community adherence groups or safe community-based medication
456 pick-up points.⁷³

457 At a macro level, harmful gender norms remain worldwide such that a large proportion of
458 youth still agree that a husband is sometimes justified in beating his wife.³² Systemic work is
459 required to eradicate such attitudes and to mitigate their impact on HIV outcomes among
460 women, such as HIV educational campaigns for youth that have a strong gender equity
461 component.⁷⁴ National legislative systems must provide frameworks for these structural changes.
462 Although in 103 countries, criminal penalties exist for IPV, their implementation varies.³² Such
463 laws must be better enacted and enforced as the national legal environments often deepen gender
464 inequality and undermine national HIV responses.

465 In conclusion, IPV could have important adverse effects on HIV epidemics by
466 contributing to HIV acquisition risks and decreasing VLS among WLHIV. Efforts to prevent
467 intimate partner violence and violence against women more broadly should be included in HIV
468 control programs and indicators of IPV collected and monitored as part of HIV surveillance. The
469 IPV/HIV syndemic needs recognition by governments and communities if we are to eliminate
470 IPV and reduce HIV risk among women.

471 **Contributions**

472 SK and MMG conceived of the study. SK performed the analyses. MMG and DP contributed to
473 the study methods and reviewing and editing the manuscript. SK wrote the initial draft of the
474 manuscript. DP, MCB, SD, JWE, FM, LS, LSC, HS, RW and MMG helped interpret the results
475 and provided valuable feedback on the policy implications of the study. All authors contributed
476 to and approved the final manuscript.

477 **Acknowledgments**

478 We are grateful and indebted to the survey teams who made their data publicly available and to
479 all survey participants.

480 **Funding**

481 This study is funded by the Canadian Institutes of Health Research. MMG's research program is
482 funded by a *Canada Research Chair* (Tier 2) in *Population Health Modeling*. SK received a *Max*
483 *E. Binz Fellowship* from McGill University.

484 **Data sharing**

485 Data used in the study are publicly available for investigators who submit an abstract and a data
486 analysis plan as part of *Demographic and Health Surveys* (DHS), *AIDS Indicator Surveys* (AIS)
487 (<https://dhsprogram.com/Data/>), *Population-based HIV Impact Assessment* (PHIA) (<https://phia-data.icap.columbia.edu/datasets>) and *South Africa National HIV Prevalence, Incidence, Behavior and Communication Survey* (SABSSM) (<http://datacuration.hsrc.ac.za/search/browse/alpha/S>).
489 Analysis code and clean data that support the findings of the study are available upon request.

491 **Declaration of interests**

492 MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc., and
493 contractual arrangements from the *Institut national de santé publique du Québec* (INSPQ), the

494 *Institut d'excellence en santé et services sociaux (INESSS), the World Health Organization, and*
495 *the Joint United Nations Programme on HIV/AIDS (UNAIDS), all outside of the submitted*
496 *work.*

497

498 References

- 499 1. Garcia-Moreno C. Violence Against Women: International Perspectives. *American*
500 *Journal of Preventive Medicine* 2000; **19**(4): 330-3.
- 501 2. Garcia-Moreno C, Heise L, Jansen HA, Ellsberg M, Watts C. Public health. Violence
502 against women. *Science* 2005; **310**(5752): 1282-3.
- 503 3. Garcia-Moreno C, Watts C. Violence against women: its importance for HIV/AIDS. *AIDS*
504 2000; **14 Suppl 3**: S253-65.
- 505 4. Martin SL, Curtis S. Gender-based violence and HIV/AIDS: recognising links and acting
506 on evidence. *Lancet* 2004; **363**(9419): 1410-1.
- 507 5. Kouyoumdjian FG, Findlay N, Schwandt M, Calzavara LM. A systematic review of the
508 relationships between intimate partner violence and HIV/AIDS. *PLoS One* 2013; **8**(11): e81044.
- 509 6. Li Y, Marshall CM, Rees HC, Nunez A, Ezeanolue EE, Ehiri JE. Intimate partner
510 violence and HIV infection among women: a systematic review and meta-analysis. *J Int AIDS*
511 *Soc* 2014; **17**: 18845.
- 512 7. Campbell JC, Baty ML, Ghandour RM, Stockman JK, Francisco L, Wagman J. The
513 intersection of intimate partner violence against women and HIV/AIDS: a review. *Int J Inj Contr*
514 *Saf Promot* 2008; **15**(4): 221-31.
- 515 8. Durevall D, Lindskog A. Intimate partner violence and HIV in ten sub-Saharan African
516 countries: what do the Demographic and Health Surveys tell us? *Lancet Glob Health* 2015; **3**(1):
517 e34-43.
- 518 9. Kouyoumdjian FG, Calzavara LM, Bondy SJ, et al. Risk factors for intimate partner
519 violence in women in the Rakai Community Cohort Study, Uganda, from 2000 to 2009. *BMC*
520 *Public Health* 2013; **13**(566).
- 521 10. Jewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power
522 inequity, and incidence of HIV infection in young women in South Africa: a cohort study. *Lancet*
523 2010; **376**(9734): 41-8.
- 524 11. Zablotska IB, Gray RH, Koenig MA, et al. Alcohol use, intimate partner violence, sexual
525 coercion and HIV among women aged 15-24 in Rakai, Uganda. *AIDS Behav* 2009; **13**(2): 225-
526 33.
- 527 12. Were E, Curran K, Delany-Moretlwe S, et al. A prospective study of frequency and
528 correlates of intimate partner violence among African heterosexual HIV serodiscordant couples.
529 *AIDS* 2011; **25**(16): 2009-18.
- 530 13. Hatcher AM, Smout EM, Turan JM, Christofides N, Stockl H. Intimate partner violence
531 and engagement in HIV care and treatment among women: a systematic review and meta-
532 analysis. *AIDS* 2015; **29**(16): 2183-94.
- 533 14. Leddy AM, Weiss E, Yam E, Pulerwitz J. Gender-based violence and engagement in
534 biomedical HIV prevention, care and treatment: a scoping review. *BMC Public Health* 2019;
535 **19**(1): 897.
- 536 15. Nelson KA, Ferrance JL, Masho SW. Intimate partner violence, consenting to HIV testing
537 and HIV status among Zambian women. *Int J STD AIDS* 2016; **27**(10): 832-9.
- 538 16. Nikolova SP, Small E, Mengo C. Components of resilience in gender: a comparative
539 analysis of HIV outcomes in Kenya. *Int J STD AIDS* 2015; **26**(7): 483-95.
- 540 17. Lyons CE, Grosso A, Drame FM, et al. Physical and Sexual Violence Affecting Female
541 Sex Workers in Abidjan, Cote d'Ivoire: Prevalence, and the Relationship with the Work
542 Environment, HIV, and Access to Health Services. *J Acquir Immune Defic Syndr* 2017; **75**(1): 9-
543 17.
- 544 18. Conroy A, Leddy A, Johnson M, Ngubane T, van Rooyen H, Darbes L. 'I told her this is
545 your life': relationship dynamics, partner support and adherence to antiretroviral therapy among
546 South African couples. *Cult Health Sex* 2017; **19**(11): 1239-53.

- 547 19. Kiarie JN, Farquhar C, Richardson BA, et al. Domestic violence and prevention of
548 mother-to-child transmission of HIV-1. *AIDS* 2006; **20**(13): 1763-9.
- 549 20. Mohammed BH, Johnston JM, Harwell JI, Yi H, Tsang KW, Haidar JA. Intimate partner
550 violence and utilization of maternal health care services in Addis Ababa, Ethiopia. *BMC Health*
551 *Serv Res* 2017; **17**(1): 178.
- 552 21. Turan JM, Bukusi EA, Onono M, Holzemer WL, Miller S, Cohen CR. HIV/AIDS stigma
553 and refusal of HIV testing among pregnant women in rural Kenya: results from the MAMAS
554 Study. *AIDS Behav* 2011; **15**(6): 1111-20.
- 555 22. Kidman R, Violari A. Dating Violence Against HIV-Infected Youth in South Africa:
556 Associations With Sexual Risk Behavior, Medication Adherence, and Mental Health. *J Acquir*
557 *Immune Defic Syndr* 2018; **77**(1): 64-71.
- 558 23. Hampanda K. Intimate Partner Violence Against HIV-Positive Women is Associated with
559 Sub-Optimal Infant Feeding Practices in Lusaka, Zambia. *Matern Child Health J* 2016; **20**(12):
560 2599-606.
- 561 24. Biomndo BC, Bergmann A, Lahmann N, Atwoli L. Intimate partner violence is a barrier to
562 antiretroviral therapy adherence among HIV-positive women: Evidence from government
563 facilities in Kenya. *PLoS One* 2021; **16**(4): e0249813.
- 564 25. Hatcher AM, Stöckl H, Christofides N, et al. Mechanisms linking intimate partner
565 violence and prevention of mother-to-child transmission of HIV: A qualitative study in South
566 Africa. *Soc Sci Med* 2016; **168**: 130-9.
- 567 26. Merrill KG, Campbell JC, Decker MR, et al. Past-Year Violence Victimization is
568 Associated with Viral Load Failure Among HIV-Positive Adolescents and Young Adults. *AIDS*
569 *Behav* 2021; **25**(5): 1373-83.
- 570 27. Hatcher AM, Brittain K, Phillips TK, Zerbe A, Abrams EJ, Myer L. Longitudinal
571 association between intimate partner violence and viral suppression during pregnancy and
572 postpartum in South African women. *AIDS* 2021; **35**(5): 791-9.
- 573 28. UNAIDS. UNAIDS Data 2021, 2021.
- 574 29. UNAIDS. Global HIV Statistics: Fact Sheet, 2021.
- 575 30. UNAIDS. Fast-Track: Ending the AIDS Epidemic by 2030, 2014.
- 576 31. Sardinha L M-GM, Stockl H, Meyer S, Garcia-Moreno C. Global, regional and national
577 prevalence estimates of physical and/or sexual intimate partner violence against women, 2018.
578 *Lancet* 2022; **399**(10327): P803-13.
- 579 32. UNAIDS. Global AIDS update: Confronting inequalities, 2021.
- 580 33. Schaefer R, Gregson S, Fearon E, Hensen B, Hallett TB, Hargreaves JR. HIV
581 prevention cascades: A unifying framework to replicate the successes of treatment cascades.
582 *Lancet HIV* 2019; **6**(1): e60-e6.
- 583 34. Hampanda KM. Intimate partner violence and HIV-positive women's non-adherence to
584 antiretroviral medication for the purpose of prevention of mother-to-child transmission in Lusaka,
585 Zambia. *Soc Sci Med* 2016; **153**: 123-30.
- 586 35. Wechsberg WM, van der Horst C, Ndirangu J, et al. Seek, test, treat: substance-using
587 women in the HIV treatment cascade in South Africa. *Addict Sci Clin Pract* 2017; **12**(1): 12.
- 588 36. Stockl H, Sardinha L, Maheu-Giroux M, Meyer SR, Garcia-Moreno C. Physical, sexual
589 and psychological intimate partner violence and non-partner sexual violence against women
590 and girls: a systematic review protocol for producing global, regional and country estimates.
591 *BMJ Open* 2021; **11**(8): e045574.
- 592 37. Giguere K, Eaton JW, Marsh K, et al. Trends in knowledge of HIV status and efficiency
593 of HIV testing services in sub-Saharan Africa, 2000-20: a modelling study using survey and HIV
594 testing programme data. *Lancet HIV* 2021; **8**(5): e284-e93.
- 595 38. Straus M. The Revised Conflict Tactics Scale. *Journal of Family Issues* 1996; **17**(3):
596 286-316.
- 597 39. Kishor S. Domestic violence measurement in the demographic and health surveys:

- 598 The history and the challenges. Geneva, Switzerland, 2005.
- 599 40. Maheu-Giroux M SL, Stöckl H, Meyer S, Godin A, Alexander M, García-Moreno C.
600 [Preprint] A framework to model global, regional, and national estimates of intimate partner
601 violence. 2022.
- 602 41. Laeyendecker O, Gray RH, Grabowski MK, et al. Validation of the Limiting Antigen
603 Avidity Assay to Estimate Level and Trends in HIV Incidence in an A/D Epidemic in Rakai,
604 Uganda. *AIDS Res Hum Retroviruses* 2019; **35**(4): 364-7.
- 605 42. WHO. HIV Incidence Measurement and Data Use. Boston, 2018.
- 606 43. Mitchell KM, Maheu-Giroux M, Dimitrov D, et al. How can progress towards Ending the
607 HIV Epidemic in the United States be monitored? *Clin Infect Dis* 2021.
- 608 44. Hallett TB, Lewis JJ, Lopman BA, et al. Age at first sex and HIV infection in rural
609 Zimbabwe. *Stud Fam Plann* 2007; **38**(1): 1-10.
- 610 45. Kouyoumdjian F. Intimate Partner Violence as a Risk Factor for Incident HIV Infection in
611 Women in Rakai, Uganda. Toronto: University of Toronto; 2014.
- 612 46. Shamu S, Abrahams N, Temmerman M, Musekiwa A, Zarowsky C. A systematic review
613 of African studies on intimate partner violence against pregnant women: prevalence and risk
614 factors. *PLoS One* 2011; **6**(3): e17591.
- 615 47. Auvert B, Buve A, Ferry B, et al. Ecological and individual level analysis of risk factors
616 for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV
617 infection. *AIDS* 2001; **15**: S15-30.
- 618 48. Nabaggala MS, Reddy T, Manda S. Effects of rural-urban residence and education on
619 intimate partner violence among women in Sub-Saharan Africa: a meta-analysis of health
620 survey data. *BMC Womens Health* 2021; **21**(1): 149.
- 621 49. Harling G, Msisha W, Subramanian SV. No association between HIV and intimate
622 partner violence among women in 10 developing countries. *PLoS One* 2010; **5**(12): e14257.
- 623 50. Solon GH, S and Wooldridge J. [Working paper] What Are We Weighting For? In:
624 Research NBoE, editor.; 2013.
- 625 51. Højsgaard S. Package 'geepack', 2022.
- 626 52. Wagman JA, Gray RH, Campbell JC, et al. Effectiveness of an integrated intimate
627 partner violence and HIV prevention intervention in Rakai, Uganda: analysis of an intervention in
628 an existing cluster randomised cohort. *Lancet Glob Health* 2015; **3**(1): e23-33.
- 629 53. McLean I, Roberts SA, White C, Paul S. Female genital injuries resulting from
630 consensual and non-consensual vaginal intercourse. *Forensic Sci Int* 2011; **204**(1-3): 27-33.
- 631 54. Dunkle KL, Decker MR. Gender-based violence and HIV: reviewing the evidence for
632 links and causal pathways in the general population and high-risk groups. *Am J Reprod*
633 *Immunol* 2013; **69**: 20-6.
- 634 55. Decker MR, Seage GR, 3rd, Hemenway D, et al. Intimate partner violence functions as
635 both a risk marker and risk factor for women's HIV infection: findings from Indian husband-wife
636 dyads. *J Acquir Immune Defic Syndr* 2009; **51**(5): 593-600.
- 637 56. Jewkes R, Sikweyiya Y, Morrell R, Dunkle K. The relationship between intimate partner
638 violence, rape and HIV amongst South African men: a cross-sectional study. *PLoS One* 2011;
639 **6**(9): e24256.
- 640 57. Jewkes R, Dunkle K, Nduna M, et al. Factors associated with HIV sero-status in young
641 rural South African women: connections between intimate partner violence and HIV. *Int J*
642 *Epidemiol* 2006; **35**(6): 1461-8.
- 643 58. Silverman JG, McCauley HL, Decker MR, Miller E, Reed E, Raj A. Coercive forms of
644 sexual risk and associated violence perpetrated by male partners of female adolescents.
645 *Perspect Sex Reprod Health* 2011; **43**(1): 60-5.
- 646 59. Pearlman DN, Averbach AR, Zierler S, Cranston K. Disparities in prenatal HIV testing:
647 evidence for improving implementation of CDC screening guidelines. *J Natl Med Assoc* 2005;
648 **97**(7): 44S-51S.

- 649 60. Etudo O, Metheny N, Stephenson R, Kalokhe AS. Intimate partner violence is linked to
650 less HIV testing uptake among high-risk, HIV-negative women in Atlanta. *AIDS Care* 2017;
651 **29**(8): 953-6.
- 652 61. Nasrullah M, Oraka E, Breiding MJ, Chavez PR. HIV testing and intimate partner
653 violence among non-pregnant women in 15 US states/territories: findings from behavioral risk
654 factor surveillance system survey data. *AIDS Behav* 2013; **17**(7): 2521-7.
- 655 62. Satyanarayana VA, Chandra PS, Vaddiparti K, Benegal V, Cottler LB. Factors
656 influencing consent to HIV testing among wives of heavy drinkers in an urban slum in India.
657 *AIDS Care* 2009; **21**(5): 615-21.
- 658 63. Raj A, Silverman JG, Amaro H. Abused women report greater male partner risk and
659 gender-based risk for HIV: findings from a community-based study with Hispanic women. *AIDS*
660 *Care* 2004; **16**(4): 519-29.
- 661 64. Sullivan KA, Messer LC, Quinlivan EB. Substance abuse, violence, and HIV/AIDS
662 (SAVA) syndemic effects on viral suppression among HIV positive women of color. *AIDS Patient*
663 *Care STDS* 2015; **29**: S42-8.
- 664 65. Espino SR, Fletcher J, Gonzalez M, Precht A, Xavier J, Matoff-Stepp S. Violence
665 screening and viral load suppression among HIV-positive women of color. *AIDS Patient Care*
666 *STDS* 2015; **29**(1): S36-41.
- 667 66. Machtinger EL, Haberer JE, Wilson TC, Weiss DS. Recent trauma is associated with
668 antiretroviral failure and HIV transmission risk behavior among HIV-positive women and female-
669 identified transgenders. *AIDS Behav* 2012; **16**(8): 2160-70.
- 670 67. Maman S, Mbwapo JK, Hogan NM, et al. HIV-positive women report more lifetime
671 partner violence: findings from a voluntary counseling and testing clinic in Dar es Salaam,
672 Tanzania. *Am J Public Health* 2002; **92**(8): 1331-7.
- 673 68. Khan MN, Islam MM. Women's attitude towards wife-beating and its relationship with
674 reproductive healthcare seeking behavior: A countrywide population survey in Bangladesh.
675 *PLoS One* 2018; **13**(6): e0198833.
- 676 69. Daftary A, Padayatchi N, Padilla M. HIV testing and disclosure: a qualitative analysis of
677 TB patients in South Africa. *AIDS Care* 2007; **19**(4): 572-7.
- 678 70. Ellsberg M, Heise L, Peña R, Agurto S, Winkvist A. Researching domestic violence
679 against women: methodological and ethical considerations. *Stud Fam Plann* 2001; **32**(1): 1-16.
- 680 71. Xia Y, Milwid RM, Godin A, et al. Accuracy of self-reported HIV-testing history and
681 awareness of HIV-positive status in four sub-Saharan African countries. *AIDS* 2021; **35**(3): 503-
682 10.
- 683 72. Heise L, Pallitto C, Garcia-Moreno C, Clark CJ. Measuring psychological abuse by
684 intimate partners: Constructing a cross-cultural indicator for the Sustainable Development
685 Goals. *SSM Popul Health* 2019; **9**: 100377.
- 686 73. Roy M, Bolton Moore C, Sikazwe I, Holmes CB. A Review of Differentiated Service
687 Delivery for HIV Treatment: Effectiveness, Mechanisms, Targeting, and Scale. *Curr HIV/AIDS*
688 *Rep* 2019; **16**(4): 324-34.
- 689 74. Sharma V, Leight J, Verani F, Tewolde S, Deyessa N. Effectiveness of a culturally
690 appropriate intervention to prevent intimate partner violence and HIV transmission among men,
691 women, and couples in rural Ethiopia: Findings from a cluster-randomized controlled trial. *PLoS*
692 *Med* 2020; **17**(8): e1003274.

693

694

695